샘플 요청 목록

 카트 문의
시장보고서
상품코드
1785724

세계의 항레트로바이러스약 시장

Anti-Retroviral Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 280 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 항레트로바이러스약 시장은 2030년까지 348억 달러에 달할 전망

2024년에 294억 달러로 추정된 세계의 항레트로바이러스약 시장은 2024-2030년의 분석 기간에 CAGR 2.9%로 성장하며, 2030년에는 348억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 멀티 클래스 병용약은 CAGR 2.8%를 기록하며, 분석 기간 종료시에는 113억 달러에 달할 것으로 예상됩니다. 뉴클레오티드 역전사 효소 저해제 부문의 성장률은 분석 기간 중 CAGR 2.7%로 추정됩니다.

미국 시장은 80억 달러, 중국은 CAGR 5.4%로 성장할 것으로 예측

미국의 항레트로바이러스약시장은 2024년에 80억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 68억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 5.4%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.1%와 2.2%로 예측됩니다. 유럽에서는 독일이 CAGR 1.6%로 성장할 것으로 예측됩니다.

세계의 항레트로바이러스약시장 - 주요 동향과 촉진요인 정리

항레트로바이러스제 수요가 증가하는 이유는 무엇인가?

HIV/AIDS의 세계적 부담은 공중보건의 큰 과제이며, 2023년 기준 HIV 감염자 수는 3,900만 명으로 추산되고 있습니다. HIV/AIDS의 확산을 억제하는 데 큰 진전이 있었지만, 신규 감염자 증가, 약제 내성 증가, 평생 치료 지속의 필요성 등으로 인해 항레트로바이러스제(ARVs)에 대한 수요가 증가하고 있습니다. 노출 전 예방약(Pre-Exposure Prophylaxis, PrEP)과 노출 후 예방약(Post-Exposure Prophylaxis, PEP)의 도입으로 ARV의 용도는 치료 외에도 확대되어 고위험군에서의 예방 노력이 강화되고 있습니다. 또한 지속형 주사제 및 부작용이 적은 차세대 ARV는 환자의 순응도와 삶의 질을 향상시켜 치료의 전망을 재구성하고 있습니다.

과학적 혁신은 ARV 치료법을 어떻게 변화시키고 있는가?

약물유전체학, 나노의학, CRISPR 기반 유전자 편집의 눈부신 발전은 보다 효과적이고 개인화된 HIV 치료의 길을 열어주고 있습니다. 장기 지속형 주사제(예: 카보테그라비르, 릴피비린 등)의 개발로 매일 복용하는 경구약에 대한 의존도가 낮아져 환자들의 편의성이 향상되었습니다. 또한 광범위 중화항체(bNAbs)는 HIV 치료의 유망 접근법으로 부상하고 있으며, 여러 바이러스 균주를 효과적으로 표적으로 삼을 수 있습니다. 인테그라아제 억제제(INSTI), 비뉴클레오시드 역전사효소 억제제(NNRTI), 프로테아제 억제제(PI)를 통합한 병용요법은 바이러스 억제율을 높이면서 내성 위험을 최소화하는 표준요법으로 자리 잡고 있습니다. 또한 AI를 활용한 신약개발 플랫폼으로 효능이 향상되고 부작용이 적은 차세대 ARV의 개발이 가속화되고 있습니다.

시장 과제와 치료 접근성에 대한 장벽은 무엇인가?

의료의 발전에도 불구하고 몇 가지 과제는 세계 항레트로바이러스제 시장에 계속 영향을 미치고 있습니다. 약제 내성은 여전히 심각한 문제이며, 일부 환자들은 1차 선택 ARV 요법에 대한 내성을 획득하고 있으며, 2차 및 3차 선택 약물의 개발이 필요한 상황입니다. 또한 특히 의료 인프라가 부족한 중저소득국가(LMICs)에서는 치료 접근성과 경제적 부담이 여전히 큰 문제로 대두되고 있습니다. HIV/AIDS와 관련된 낙인은 조기 진단과 치료 시작을 방해하는 요인으로, 보다 강력한 공중보건 캠페인과 지역 사회 기반 개입 프로그램이 필요합니다. 또한 규제 장벽, 까다로운 승인 절차, 공급망 혼란은 개발도상국에서 혁신적인 ARV 제제의 적시 공급에 계속 영향을 미치고 있습니다.

항레트로바이러스제 시장 성장의 원동력은?

항레트로바이러스제 시장의 성장은 전 세계 HIV/AIDS 유병률 증가, HIV 치료 프로그램에 대한 정부 자금 지원 증가, 효능이 강화되고 부작용이 감소된 새로운 ARV 제제 출시 등 여러 요인에 의해 주도되고 있습니다. 세계 에이즈, 결핵, 말라리아 퇴치 기금(Global Fund), PEPFAR, UNAIDS 등이 주도하는 민관 파트너십의 확대로 인해 치료받지 못하는 지역에서 저렴한 ARV에 대한 접근성이 크게 개선되었습니다. 또한 장기지속형 치료제와 차세대 HIV 치료제로의 전환은 환자들의 복약 순응도를 고려한 보다 편리한 치료제를 찾는 환자들 수요로 인해 시장 성장을 촉진하고 있습니다. 신흥 시장에서는 제네릭 ARV의 채택이 증가하고 있으며, 서방형 약물전달 시스템의 기술적 발전으로 인해 접근성과 경제성이 더욱 향상되고 있습니다. 또한 HIV의 기능성 치료제 및 치료용 백신 개발이 진행되고 있는 것도 시장 전망 궤도를 형성하며 향후 10년간 큰 폭의 확장을 위한 자리매김을 하고 있습니다.

부문

약제 클래스별(다제 병용요법약, 뉴클레오티드계 역전사 효소 저해제(NRTI), 비뉴클레오티드계 역전사 효소 저해제(NNRTI), 프로테아제 저해제, 인테그라아제 저해제, 기타 약제 클래스), 약제 유형별(브랜드약, 제네릭 의약품),

조사 대상 기업의 예

  • AbbVie, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc
  • GSK Plc
  • Jaguar Health
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris, Inc.

AI 통합

당사는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.19

Global Anti-Retroviral Drugs Market to Reach US$34.8 Billion by 2030

The global market for Anti-Retroviral Drugs estimated at US$29.4 Billion in the year 2024, is expected to reach US$34.8 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Multi-Class Combination Drugs, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$11.3 Billion by the end of the analysis period. Growth in the Nucleoside Reverse Transcriptase Inhibitors segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.0 Billion While China is Forecast to Grow at 5.4% CAGR

The Anti-Retroviral Drugs market in the U.S. is estimated at US$8.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.8 Billion by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Anti-Retroviral Drugs Market - Key Trends & Drivers Summarized

Why Is the Demand for Anti-Retroviral Drugs Increasing?

The global burden of HIV/AIDS continues to be a major public health challenge, with an estimated 39 million people living with HIV as of 2023. While significant strides have been made in controlling the epidemic, the increasing number of new infections, rising drug resistance, and the need for lifelong treatment adherence have fueled demand for anti-retroviral drugs (ARVs). The introduction of Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) has expanded ARV applications beyond treatment, enhancing prevention efforts in high-risk populations. Additionally, long-acting injectable therapies and next-generation ARVs with fewer side effects are reshaping the treatment landscape, improving patient adherence and quality of life.

How Are Scientific Innovations Transforming ARV Therapies?

Significant advancements in pharmacogenomics, nanomedicine, and CRISPR-based gene editing are paving the way for more effective and personalized HIV treatments. The development of long-acting injectables (e.g., Cabotegravir and Rilpivirine) has reduced the dependency on daily oral medications, enhancing convenience for patients. Moreover, broadly neutralizing antibodies (bNAbs) are emerging as a promising approach in HIV therapy, targeting multiple strains of the virus with high efficacy. Combination therapies integrating integrase inhibitors (INSTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs) are becoming the gold standard, minimizing resistance risks while improving viral suppression rates. Additionally, AI-driven drug discovery platforms are expediting the development of next-generation ARVs with improved potency and fewer side effects.

What Are the Market Challenges and Barriers to Treatment Access?

Despite medical advancements, several challenges continue to impact the global anti-retroviral drugs market. Drug resistance remains a critical issue, with some patients developing resistance to first-line ARV regimens, necessitating the development of second- and third-line therapies. Additionally, treatment accessibility and affordability remain major concerns, particularly in low- and middle-income countries (LMICs), where healthcare infrastructure is often inadequate. The stigma surrounding HIV/AIDS further hinders early diagnosis and treatment initiation, necessitating stronger public health campaigns and community-based intervention programs. Furthermore, regulatory hurdles, stringent approval processes, and supply chain disruptions continue to affect the timely availability of innovative ARV formulations in developing regions.

What’s Driving the Growth of the Anti-Retroviral Drugs Market?

The growth in the anti-retroviral drugs market is driven by several factors, including the rising global prevalence of HIV/AIDS, increasing government funding for HIV treatment programs, and the launch of novel ARV formulations with enhanced efficacy and reduced side effects. The expansion of public-private partnerships, such as those spearheaded by the Global Fund, PEPFAR, and UNAIDS, has significantly improved access to affordable ARVs in underserved regions. Moreover, the shift toward long-acting therapies and next-generation HIV treatments is propelling market growth, as patients seek more convenient and adherence-friendly options. The increasing adoption of generic ARVs in emerging markets, along with technological advancements in sustained-release drug delivery systems, is further driving accessibility and affordability. Additionally, the ongoing development of HIV functional cures and therapeutic vaccines continues to shape the future trajectory of the market, positioning it for significant expansion in the coming decade.

SCOPE OF STUDY:

The report analyzes the Anti-Retroviral Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors, Integrase Inhibitors, Other Drug Classes); Drug Type (Branded Drugs, Generic Drugs);

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • AbbVie, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc
  • GSK Plc
  • Jaguar Health
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Anti-Retroviral Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global HIV Prevalence Fueling Demand for Anti-Retroviral Therapies
    • Growing Innovations in Long-Acting Anti-Retroviral Drug Formulations
    • Increasing Adoption of Fixed-Dose Combination Therapies for HIV Treatment
    • Expanding Role of AI & Big Data in Personalized Anti-Retroviral Drug Development
    • Surging Investments in Pediatric & Geriatric HIV Treatment Solutions
    • Technological Advancements in Nanomedicine for Improved Drug Delivery
    • Growing Demand for Affordable & Accessible Anti-Retroviral Therapies
    • Increasing Research in HIV Cure Strategies & Functional Remission Approaches
    • Expanding Availability of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention
    • Rising Integration of Digital Health & Telemedicine in HIV Treatment Management
    • Increasing Public-Private Partnerships for Advancing Anti-Retroviral Research
    • Emerging Role of mRNA & Gene Therapy in Next-Generation HIV Treatments
    • Expansion of Government Initiatives & Funding for HIV Treatment Access
    • Growing Adoption of Community-Based Distribution Models for Anti-Retrovirals
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Anti-Retroviral Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Anti-Retroviral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Anti-Retroviral Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Multi-Class Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Multi-Class Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Multi-Class Combination Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Nucleoside Reverse Transcriptase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Nucleoside Reverse Transcriptase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Nucleoside Reverse Transcriptase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Non-Nucleoside Reverse Transcriptase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Non-Nucleoside Reverse Transcriptase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Non-Nucleoside Reverse Transcriptase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Protease Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Protease Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Protease Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Integrase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Integrase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Integrase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Branded Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Branded Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Branded Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • JAPAN
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • CHINA
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • EUROPE
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Anti-Retroviral Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Anti-Retroviral Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • FRANCE
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • GERMANY
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Anti-Retroviral Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Anti-Retroviral Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • INDIA
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Anti-Retroviral Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Anti-Retroviral Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Anti-Retroviral Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Anti-Retroviral Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • AFRICA
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제